When Does Wegovy Patent Protection End in Europe?
Wegovy's primary patent protection in Europe is anticipated to expire around late 2031 [1]. However, the exact timeline can be influenced by various factors, including patent extensions and potential legal challenges [1][2].
What are the key patents protecting Wegovy?
The main patent safeguarding Wegovy, specifically semaglutide, is European Patent EP 2353413 B1 [1]. This patent covers the active pharmaceutical ingredient and its use in treating obesity [3].
Could Wegovy's patent life be extended?
Patent term extensions are possible in Europe to compensate for regulatory review delays. These extensions are typically granted for a maximum of five years, which could potentially push Wegovy's protection beyond 2031, depending on when marketing authorizations were obtained [2].
How do patent challenges affect Wegovy's exclusivity?
Patent litigation can significantly impact the timeline of generic entry. If Wegovy's patents are challenged in court, it could lead to earlier invalidation, allowing for the introduction of generic versions sooner than the stated expiry date [1]. Conversely, successful defense of the patents would maintain their validity until their scheduled end.
When might generic versions of Wegovy become available in Europe?
Generic versions of Wegovy could become available after the expiry of its primary patent protection and any granted extensions, assuming no further patent barriers exist and regulatory approval pathways are cleared [1][2]. The earliest possible entry for generics would likely be after late 2031, assuming no successful patent challenges or extensions alter this timeline.
What is the significance of Wegovy patent expiry for pricing and access?
The expiry of patent protection is a critical factor that typically leads to increased competition from generic manufacturers. This increased competition is often associated with a reduction in drug prices, potentially improving access for patients [1].
How does Wegovy's patent situation compare to other obesity medications?
Information regarding the specific patent expiry timelines for other obesity medications is not provided.
Who manufactures Wegovy?
Wegovy is manufactured by Novo Nordisk [4].
Where can I find more information on Wegovy's patent status?
Detailed information on Wegovy's patent status in Europe and globally can be found at DrugPatentWatch.com [1].
---
Sources:
1. DrugPatentWatch.com. "Wegovy patent expiry europe." Accessed [Insert Date Accessed]. https://drugpatentwatch.com/
2. European Patent Office. "Supplementary Protection Certificates (SPCs)." Accessed [Insert Date Accessed].
3. European Patent EP 2353413 B1. Accessed [Insert Date Accessed].
4. Novo Nordisk. "Wegovy® (semaglutide) injection 2.4 mg." Accessed [Insert Date Accessed].